Drug Pricing Reform Gathers Steam (Part 2)
FDA Law Blog
SEPTEMBER 14, 2021
This bill, which addresses numerous areas of the economy, public health, and government regulation, includes Subtitle E, Drug Pricing. A manufacturer that failed to provide access to the MFP would be subject to a civil monetary penalty of ten times the excessive price charged. The Part B rebate would exclude vaccines as well.
52 
Let's personalize your content